BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone919-859-1302
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$20.65 million
Profitability
Miscellaneous
Employees100
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions
What is BioCryst Pharmaceuticals' stock symbol?
BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."
How were BioCryst Pharmaceuticals' earnings last quarter?
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) issued its quarterly earnings results on Monday, March, 4th. The biotechnology company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. The biotechnology company earned $2.73 million during the quarter, compared to analyst estimates of $2.39 million. BioCryst Pharmaceuticals had a negative net margin of 490.25% and a negative return on equity of 175.83%. View BioCryst Pharmaceuticals' Earnings History.
When is BioCryst Pharmaceuticals' next earnings date?
What price target have analysts set for BCRX?
9 equities research analysts have issued twelve-month price targets for BioCryst Pharmaceuticals' shares. Their predictions range from $8.00 to $18.00. On average, they anticipate BioCryst Pharmaceuticals' share price to reach $12.50 in the next twelve months. This suggests a possible upside of 53.2% from the stock's current price. View Analyst Price Targets for BioCryst Pharmaceuticals.
What is the consensus analysts' recommendation for BioCryst Pharmaceuticals?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioCryst Pharmaceuticals.
Has BioCryst Pharmaceuticals been receiving favorable news coverage?
Headlines about BCRX stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioCryst Pharmaceuticals earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the near term.
Who are some of BioCryst Pharmaceuticals' key competitors?
Some companies that are related to BioCryst Pharmaceuticals include Allogene Therapeutics (ALLO), Repligen (RGEN), Denali Therapeutics (DNLI), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Audentes Therapeutics (BOLD), Alector (ALEC), Orchard Therapeutics (ORTX), Atara Biotherapeutics (ATRA), Momenta Pharmaceuticals (MNTA), Rubius Therapeutics (RUBY) and Iovance Biotherapeutics (IOVA).
What other stocks do shareholders of BioCryst Pharmaceuticals own?
Who are BioCryst Pharmaceuticals' key executives?
BioCryst Pharmaceuticals' management team includes the folowing people:
- Mr. Jon P. Stonehouse, CEO, Pres & Director (Age 58)
- Mr. Thomas R. Staab II, CFO, Principal Accounting Officer, Sr. VP & Treasurer (Age 51)
- Dr. William P. Sheridan, Chief Medical Officer & Sr. VP (Age 64)
- Dr. Yarlagadda S. Babu, Sr. VP of Drug Discovery (Age 66)
- Ms. Lynne M. Powell, Chief Commercial Officer & Sr. VP (Age 52)
Who are BioCryst Pharmaceuticals' major shareholders?
BioCryst Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Quantitative Systematic Strategies LLC (0.01%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Fred E Cohen, Lynne Powell, Steve Aselage, Thomas R Staab II and William P Sheridan. View Institutional Ownership Trends for BioCryst Pharmaceuticals.
Which institutional investors are selling BioCryst Pharmaceuticals stock?
BCRX stock was sold by a variety of institutional investors in the last quarter, including Quantitative Systematic Strategies LLC. Company insiders that have sold BioCryst Pharmaceuticals company stock in the last year include Alane P Barnes, Lynne Powell, Thomas R Staab II and William P Sheridan. View Insider Buying and Selling for BioCryst Pharmaceuticals.
How do I buy shares of BioCryst Pharmaceuticals?
Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioCryst Pharmaceuticals' stock price today?
One share of BCRX stock can currently be purchased for approximately $8.16.
How big of a company is BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals has a market capitalization of $899.80 million and generates $20.65 million in revenue each year. The biotechnology company earns $-101,250,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. BioCryst Pharmaceuticals employs 100 workers across the globe.
What is BioCryst Pharmaceuticals' official website?
How can I contact BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at 919-859-1302 or via email at [email protected]
MarketBeat Community Rating for BioCryst Pharmaceuticals (NASDAQ BCRX)
MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. Vote "Outperform" if you believe BCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
